In colon cancer, the negative predictive value of KRAS mutation status for the anti-EGFR antibodies efficacy has been reported first in retrospective studies then definitively confirmed by retrospective analysis of tumors of patients included in large prospective trials [99,100]. This evidence concerns the gene EGFR and malignant colon neoplasm.